Literature DB >> 11788685

A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy.

Anil K Agarwal1, Abhimanyu Garg.   

Abstract

Familial partial lipodystrophies (FPL) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia. Recently, lamin A/C gene mutations were found in patients with FPL, Dunnigan variety. However, the genetic basis of other phenotypes remains unknown. We studied peroxisome proliferator-activated receptor-gamma (PPARgamma) gene as a candidate gene in seven FPL patients who did not appear to have Dunnigan variety. Analysis of the coding region of PPARG revealed C to T heterozygous mutation at nucleotide 1273 in exon 6 which changes a highly conserved residue, arginine at position 425 to cysteine (R425C) in the patient FX200.21. The patient is a 64-year-old nonHispanic white woman who developed diabetes mellitus and hypertriglyceridemia at age 32 years and lipodystrophy of the extremities and face at age 50 years. She also had hirsutism. Anthropometry and whole body magnetic resonance imaging revealed marked loss of sc fat particularly from the extremities but sc truncal fat was slightly increased. None of the four unaffected family members harbored the mutation. We conclude that heterozygous, R425C, mutation in PPARG could be the molecular basis for one of the familial partial lipodystrophy phenotypes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11788685     DOI: 10.1210/jcem.87.1.8290

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  77 in total

Review 1.  Lipoatrophic diabetes and other related syndromes.

Authors:  Elif Arioglu Oral
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

Review 2.  Autophagic degradation of mitochondria in white adipose tissue differentiation.

Authors:  Scott J Goldman; Yong Zhang; Shengkan Jin
Journal:  Antioxid Redox Signal       Date:  2011-03-16       Impact factor: 8.401

Review 3.  Lipodystrophy: pathophysiology and advances in treatment.

Authors:  Christina G Fiorenza; Sharon H Chou; Christos S Mantzoros
Journal:  Nat Rev Endocrinol       Date:  2010-11-16       Impact factor: 43.330

Review 4.  Lipodystrophies: adipose tissue disorders with severe metabolic implications.

Authors:  Víctor A Cortés; Marta Fernández-Galilea
Journal:  J Physiol Biochem       Date:  2015-04-02       Impact factor: 4.158

5.  New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.

Authors:  Angelika Lüdtke; Janine Buettner; Hartmut H-J Schmidt; Howard J Worman
Journal:  J Med Genet       Date:  2007-09       Impact factor: 6.318

Review 6.  Polluted Pathways: Mechanisms of Metabolic Disruption by Endocrine Disrupting Chemicals.

Authors:  Mizuho S Mimoto; Angel Nadal; Robert M Sargis
Journal:  Curr Environ Health Rep       Date:  2017-06

Review 7.  PPARgamma in human and mouse physiology.

Authors:  Sami Heikkinen; Johan Auwerx; Carmen A Argmann
Journal:  Biochim Biophys Acta       Date:  2007-03-27

8.  Unbuckling lipodystrophy from insulin resistance and hypertension.

Authors:  Robert A Hegele; Todd Leff
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

9.  Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma.

Authors:  Yau-Sheng Tsai; Hyo-Jeong Kim; Nobuyuki Takahashi; Hyung-Suk Kim; John R Hagaman; Jason K Kim; Nobuyo Maeda
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

Review 10.  Obesity and lipodystrophy--where do the circles intersect?

Authors:  Farid F Chehab
Journal:  Endocrinology       Date:  2008-01-17       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.